Skip to content

A Clinical Investigation of the Benefit: BTE Hearing Aids Versus ITE Hearing Aids

A Clinical Investigation of the Benefit of Directionality as a Function of Microphone Location: BTE Hearing Aids Versus ITE Hearing Aids

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04168229
Enrollment
17
Registered
2019-11-19
Start date
2018-07-12
Completion date
2018-08-13
Last updated
2019-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss

Brief summary

The current study will evaluate a new in-the-ear (ITE) hearing aid hardware. The goal is to evaluate the audiological performance, usability, feature function, and to identify unexpected or unwanted behaviour from the devices. The study plans to compare the behind-the-ear (BTE) hardware style with the ITE devices regarding the benefit received from different microphone locations.

Detailed description

Hearing aids constantly undergo incremental improvements from already marketed devices. The new devices are expected to perform as well or better than the previous ITE devices. The aim of the testing is to grant quality control prior to product launch according to Bernafon development requirements. The current study will evaluate a new ITE hearing aid hardware. The firmware driving the hearing aid has already been sold on the market using the BTE hardware for almost one year and will now be launched using the ITE custom hardware. The goal is to evaluate the audiological performance, usability, feature function, and to identify unexpected or unwanted behaviour from the devices. The study plans to compare the two hardware styles regarding the benefit received from different microphone locations. As human subjects are involved the validation falls under the definition of a clinical investigation. The validation will address the performance of the new chip using the ITE hardware, and ensure that there is no reduction in speech understanding between using the BTE and ITE hardware styles. Evaluating the overall performance of the Mermaid 9 ITE devices is important to validate that the end user is satisfied with the devices and that all user requirements are fulfilled. All features available in Mermaid 9 have been validated and are currently used on the market in Mermaid 9 BTE devices.

Interventions

DEVICEMermaid 9 ITE

A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.

DEVICEMermaid 9 BTE

A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.

Sponsors

Bernafon AG
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Masking is not possible as the differences in hardware between the devices is obvious. The subjects and Investigator will recognize which device is the new one and which is the comparator.

Intervention model description

The study is a controlled, open-label, comparative trial using a cross-over design. The subjects first wore the BTE Hearing aids and then the ITE.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All classifications of hearing loss (sensorineural, conductive, mixed) * If the hearing loss is conductive or mixed it must be approved for amplification by a physician * All shapes of hearing loss (flat, sloping, reverse slope, notch) * Severity ranging from mild to severe * German speaking * Current hearing aid users * Both genders * Ages 18 and older * Ability and willingness to sign the consent form

Exclusion criteria

* Contraindications for amplification * Active ear disease * Inability to follow the procedures of the study due to language problems, psychological disorders, dementia, or other cognitive problems of the participant * A reduced mobility making them unable to attend weekly study appointments * Uncooperative so that it is not possible to record a valid pure tone audiogram * A strongly reduced dexterity * Central hearing disorders * Bernafon employees * Family members of Bernafon employees

Design outcomes

Primary

MeasureTime frameDescription
Speech Intelligibility PerformanceThrough study completion, an average of one month.Speech test scores will be measured with speech reception thresholds (SRTs) of speech in noise in three conditions: unaided, aided with the BTE device, and aided with the new ITE device. The test is the Oldenburg Sentence test (OLSA) and uses nonsense sentences. The score is measured by the the signal-to-noise ratio (SNR) at which 50% of words in a sentence list are correctly repeated. The speech is always presented at 65 decibels (dB) and the background noise varies to maintain the 50% correct. A lower SNR score indicates a better score. The maximum score will be 15 dB and the minimum will be -5 dB.
Word RecognitionThrough study completion, an average of one month.Word recognition test scores will be measured with speech reception thresholds (SRTs) of speech in noise in three conditions: unaided, aided with the BTE device, and aided with the new ITE device. The test is called the Göttinger sentence test (GÖSA) and uses content relevant sentences that subjects repeat . The score is measured by the the signal-to-noise ratio (SNR) at which 50% of words in a sentence list are correctly repeated. The speech is always presented at 65 decibels (dB) and the background noise varies to maintain the 50% correct. A lower SNR score indicates a better score. The maximum score will be 15 dB and the minimum will be -5 dB.

Secondary

MeasureTime frameDescription
Subjective Performance of Aided BenefitThrough study completion, an average of one month.The subjective performance for the new device will be measured with the APHAB questionnaire (Abbreviated Hearing Aid Benefit Profile). The questionnaire is a list of 24 statement that the subjects must agree or disagree with using a scale of units from A to G (A being Always and G being Never). Each letter has a corresponding score used for the calculation: A receives 99, B receives 87, C receives 75, D receives 50, E receives 25, F receives 12, and G receives 1. An average for each subscale is calculated, and a global or overall score can be calculated by taking the mean of the three positive subscales (Ease of communication, Background noise, and Reverberation). For these three subscales a higher score indicates a better performance. The highest possible score is 99 and the lowest is 1. The fourth scale (Aversiveness) is a negative scale meaning that a higher score means a worse performance. The highest possible score is 99 and the lowest is 1.

Other

MeasureTime frameDescription
Adverse EventsThrough study completion, an average of one month.The number of adverse events reported including adverse events (AEs) related to the device will be used to measure the outcome. Adverse Events will be collected in an interview with the subjects during the Appointment. The minimum number of adverse Events possible is 0 and the maximum is infinite. A lower number means a better Outcome.
Unexpected device behaviorThrough study completion, an average of one monthSubjects will a questionnaire to report unexpected behavior. A 5-point scale is used with 0 being the lowest answer possible (never occuring) and 5 being the highest answer possible (occuring often). A lower scale is a better score.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026